创伤性脑损伤后神经炎症演变中右美托咪定的定制治疗剂量
该研究采用小鼠落体脑损伤模型,伤后0.5小时腹腔注射生理盐水(对照组)或右美托咪定40 μg/kg、200 μg/kg(药物组),于伤后第1天或第3天处死,进行组织病理学和免疫荧光检查。结果显示低剂量右美托咪定在两个时间点均抑制NLRP3和白细胞介素-1β;高剂量右美托咪定在晚期显著减少小胶质细胞和T细胞的迁移与运动,并改善该时期的神经功能结局。作者结论认为不同剂量右美托咪定通过抑制神经炎症过程的不同组分、在不同时间进程减轻神经炎症,有助于神经恢复,提示右美托咪定可能是TBI患者镇静镇痛的选择。
要点
- 小鼠落体脑损伤后0.5小时腹腔注射右美托咪定40 μg/kg或200 μg/kg,对照组注射生理盐水。
- 低剂量右美托咪定在伤后第1天和第3天均抑制NLRP3和白细胞介素-1β。
- 高剂量右美托咪定在晚期显著减少小胶质细胞和T细胞的迁移与运动。
- 高剂量右美托咪定在晚期改善神经功能结局,免疫细胞仅在高剂量晚期受影响。
- 作者认为右美托咪定可能是TBI患者镇静镇痛的选择。
适用人群与场景
- 小鼠落体脑损伤模型,伤后0.5小时给药,于伤后第1天或第3天处死评估。
处置流程与药物剂量
- 伤后0.5小时腹腔注射右美托咪定40 μg/kg或200 μg/kg,对照组注射生理盐水。
- 神经功能评估采用改良神经严重程度评分,于处死前进行。
研究设计与关键结果
- 研究类型为小鼠实验研究;脑损伤采用落体模型;伤后0.5小时腹腔注射生理盐水(对照组)或右美托咪定40 μg/kg、200 μg/kg(药物组);于伤后第1天或第3天处死,进行苏木精-伊红染色和免疫荧光(Iba1、NLRP3、白细胞介素-1β、CD3)检查;非参数数据多组比较用Kruskal-Wallis检验,两组比较用Mann-Whitney U检验;结果以均值±均值标准误表示。
- 低剂量右美托咪定在伤后第1天和第3天均抑制NLRP3和白细胞介素-1β。
- 高剂量右美托咪定在晚期显著减少小胶质细胞和T细胞的迁移与运动。
- 免疫细胞仅在高剂量右美托咪定的晚期受影响,高剂量右美托咪定在同一时期改善神经功能结局。
证据类型、等级与局限
- 证据类型:小鼠实验研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在小鼠脑外伤模型中不同剂量右美托咪定通过抑制神经炎症过程的不同组分、在不同时间进程减轻神经炎症,有助于神经恢复;这些结果提示右美托咪定可能是TBI患者镇静镇痛的选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Understanding the secondary damage mechanisms of traumatic brain injury (TBI) is essential for developing new therapeutic approaches. Neuroinflammation has a pivotal role in secondary brain injury after TBI. Activation of NLRP3 inflammasome complexes results in the secretion of proinflammatory mediators and, in addition, later in the response, microglial activation and migration of the peripheral immune cells into the injured brain are observed. Therefore, these components involved in the inflammatory process are becoming a new treatment target in TBI. Dexmedetomidine (Dex) is an effective drug, widely used over the past few years in neurocritical care units and during surgical operations for sedation and analgesia, and has anti-inflammatory effects, which are shown in in vivo studies. The aim of this original research is to discuss the anti-inflammatory effects of different Dex doses over time in TBI.
METHODS: Brain injury was performed by using a weight-drop model. Half an hour after the trauma, intraperitoneal saline was injected into the control groups and 40 and 200 μg/kg of Dex were given to the drug groups. Neurological evaluations were performed with the modified Neurological Severity Score before being killed. Then, the mice were killed on the first or the third day after TBI and histopathologic (hematoxylin-eosin) and immunofluorescent (Iba1, NLRP3, interleukin-1β, and CD3) findings of the brain tissues were examined. Nonparametric data were analyzed by using the Kruskal-Wallis test for multiple comparisons, and the Mann-Whitney U-test was done for comparing two groups. The results are presented as mean ± standard error of mean.
RESULTS: The results showed that low doses of Dex suppress NLRP3 and interleukin-1β in both terms. Additionally, high doses of Dex cause a remarkable decrease in the migration and motility of microglial cells and T cells in the late phase following TBI. Interestingly, the immune cells were influenced by only high-dose Dex in the late phase of TBI and it also improves neurologic outcome in the same period.
CONCLUSIONS: In the mice head trauma model, different doses of Dex attenuate neuroinflammation by suppressing distinct components of the neuroinflammatory process in a different timecourse that contributes to neurologic recovery. These results suggest that Dex may be an appropriate choice for sedation and analgesia in patients with TBI.
参考来源
- Karakaya D, Cakir-Aktas C, Uzun S, et al. Tailored Therapeutic Doses of Dexmedetomidine in Evolving Neuroinflammation after Traumatic Brain Injury. Neurocrit Care. 2021. PMID: 34782991. doi:10.1007/s12028-021-01381-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。